Gan & Lee Pharmaceuticals - Insulin Biosimilars: Meeting China's Diabetes Challenge скачать в хорошем качестве

Gan & Lee Pharmaceuticals - Insulin Biosimilars: Meeting China's Diabetes Challenge

Research into Biosimilars is leading to a potential paradigm shift in the way diabates is treated around the world. Biosimilars are insulin analogues which might provide faster or longer lasting control of blood glucose levels. This kind of research is increasingly urgent in China, where the population is seeing rapid increases in the prevalence of diabetes, coming close to 1 in 10 adults, around the same level as that of the United States. In China, where the cost of insulin products is often prohibitive for many people in the country, leading Chinese pharamaceutical companies are working to bring new products to the market to meet the needs of Chinese increasing population of people living with diabates. Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since they began in 1998 Gan & Lee has focused on research and development into insulin production, as well as development of biosimilars. Their products are widely used throughout China, as well as increasingly in the USA and beyond, as they continue to provide quality products that meet the rigorous demands of international regulators, often at lower cost.